109 results about "Vitreous Humors" patented technology

A critical element of a retinal prosthesis is the stimulating electrode array, which is placed in close proximity to the retina. It is via this interface that a retinal prosthesis electrically stimulates nerve cells to produce the perception of light. The impedance load seen by the current driver consists of the tissue resistance and the complex electrode impedance. The results show that the tissue resistance of the retina is significantly greater than that of the vitreous humor in the eye. Circuit models of the electrode-retina interface are used to parameterize the different contributors to the overall impedance.

An enzymatic method is provided for treating ophthalmic disorders of the mammalian eye. Prevention of neovascularization and the increased rate of clearance from the vitreous of materials toxic to retina is accomplished by administering an amount of hyaluronidase effective to liquefy the vitreous humor of the treated eye without causing toxic damage to the eye. Liquefaction of the vitreous humor increases the rate of liquid exchange from the vitreal chamber. This increase in exchange removes those materials and conditions whose presence causes ophthalmological and retinal damage.

A method and device for reducing the damaging effects of radiant energy, blast, or concussive events includes applying pressure to at least one jugular vein to reduce the egress of blood from the cranial cavity during or before the incidence of the imparting event. Reducing blood outflow from the cranial cavity increases intracranial volume and / or pressure of the cerebrospinal fluid to reduce the risk of traumatic brain injury and injuries to the spinal column. Reducing blood outflow further increases the intracranial pressure and volume, and thereby increases the pressure and volume of the cochlear fluid, the vitreous humor and the cerebrospinal fluid to thereby reduce the risk of injury to the inner ear, internal structure of the eye and of the spinal column. In addition, increasing intracranial pressure and volume reduces the likelihood of brain injury and any associated loss of olfactory function.

The present invention generally relates to an apparatus and processes for preventing or delaying presbyopia. More particularly, the present invention relates to processes and apparatus for ablating epithelial cells in the germinative zone or the pregerminative zone of the crystalline lens of the eye so that onset or progression of presbyopia or one or more symptoms is de-layed or prevented. The present invention also relates to processes and apparatus for promoting formation of suture lines in the crystalline lens of the eye so that onset or progression of presbyopia or one or more symptoms is delayed or prevented. The present invention also relates to processes and apparatus for creating disruptions in the vitreous humor of the eye.

A method is disclosed for creating a separation of posterior cortical vitreous from the retina of the eye. The method includes the step of introducing plasmin into the vitreous humor of the eye. The plasmin may be introduced either by injection or through a sustained release device. Optionally, other enzymes, polysaccharides, and / or glycoproteins are intermixed with the plasmin.

A method and device for reducing the damaging effects of radiant energy, blast, or concussive events includes applying pressure to at least one jugular vein to reduce the egress of blood from the cranial cavity during or before the incidence of the imparting event. Reducing blood outflow from the cranial cavity increases intracranial volume and / or pressure of the cerebrospinal fluid to reduce the risk of traumatic brain injury and injuries to the spinal column. Reducing blood outflow further increases the intracranial pressure and volume, and thereby increases the pressure and volume of the cochlear fluid, the vitreous humor and the cerebrospinal fluid to thereby reduce the risk of injury to the inner ear, internal structure of the eye and of the spinal column. In addition, increasing intracranial pressure and volume reduces the likelihood of brain injury and any associated loss of olfactory function.

A reading enhancement device for preventing and / or treating presbyopia of the eye. The enhancement device is sutured to an outer wall of the sclera for buckling and compressing a portion of the sclera and the ciliary body inwardly and perpendicular to the plane of the sclera and exerting a posterior compression force toward the vitreous humor in the rear of the eye. The enhancement device includes a compression body with a front of the body having semi-circular convex surface. The compression body made of a non-metallic, synthetic polymer. The convex surface is used for engaging, buckling and compressing both a portion of the sclera and the ciliary body of the eye. The compression body also includes an enlarged, rounded first and second end portions and an elongated center portion with the convex surface formed thereon. Also, the compression body includes a rear having an outwardly extending rib portion with a pair of grooves at opposite ends of the rib portion. The grooves and the enlarged, rounded first and second end portions are used to aid the eye surgeon in suturing and securing the enhancement device to the side of the eye.

The present invention provides a biomarker composition for detecting diabetic retinopathy comprising at least one protein selected from the group consisting of proteins as set forth in SEQ ID NOS: 1 to 169. And also, the present invention provides a kit for diagnosing diabetic retinopathy, comprising a molecule specifically binding to at least one protein selected from the group consisting of proteins as set forth in SEQ ID NOS: 1 to 169. It has been newly found that 105 proteins as set forth in SEQ ID NOS: 1 to 105 are significantly over-expressed in the vitreous humors obtained from PDR patients, while 64 proteins as set forth in SEQ ID NOS: 106 to 169 are significantly over-expressed in those obtained from normal people. Therefore, the proteins can be used for biomarker capable of detecting diabetic retinopathy. The biomarker can provide fundamental information in researching vitreoretinal disorders, such as diabetic retinopathy. Especially, the newly found proteins may be applied to a kit for diagnosing diabetic retinopathy with a molecule specifically binding thereto, e.g., a monoclonal antibody. And also, it has been newly found that the levels of thyroxine-binding globulin precursor (TBG) in both vitreous and plasma of PDR and NPDR states and in plasma of diabetes mellitus state, are outstandingly higher than in non-diabetic control (MH or normal control). Therefore, TBG may be applied to a diabetes mellitus biomarker, and a kit for diagnosing diabetes mellitus with a molecule specifically binding thereto.

The invention discloses a method for detecting durability of an overflow brick. The detection method comprises the following steps of: horizontally placing a rectangular to-be-detected overflow brick into a high temperature resistant container in a manner of being vertical to the height direction, respectively placing two lengthwise ends of the to-be-detected overflow brick onto two supporting bases, so as to ensure that creep spaces are formed at the lower surface of the to-be-detected overflow brick and the bottom of the high temperature resistant container; performing high-temperature erosion treatment on the to-be-detected overflow brick in a vitreous humor so as to enable the overflow brick to creep downwards in the height direction, thereby obtaining the creep overflow brick; calculating the high temperature creep rate sigma of the overflow brick by use of a formula I, wherein the formula I is as shown in the description; the lower the high temperature creep rate sigma is, the better the durability of the to-be-detected overflow brick is. The detection method disclosed by the invention is capable of detecting the high temperature creep rate of the overflow brick so as to detect the durability of the overflow brick.

The subject invention utilizes the characteristics of in vivo tissue impedances to provide an embodiment of a retinal rake capable of providing a visible and / or preferably an audible signal to a surgeon that more clearly indicates which type of tissue(s) is in contact with the retinal rake. A preferred embodiment comprises a handheld, battery operated retinal rake having two electrodes, wherein at least one electrode is the modified retinal rake. Upon contact with different optical tissues, e.g., epiretinal membranes, retinal tissue, vitreous humor, etc., the electrodes detect varying impedances which are translated by onboard circuitry into various signals that indicate what type of tissue, fluid, structure, etc. is in contact with the retinal rake.

The invention relates to polypeptide for preventing and treating angiogenesis and application thereof. The invention also relates to the preparation and the application of the polypeptide and a medicinal composition containing the polypeptide. The polypeptide has a plurality of types of advantages, such as small molecular weight for permeating various eye tissue barriers, high water solubility for keeping high concentration in neutral tear, aqueous humor and vitreous humor, and the like.